Home LiteratureArticle Details
PMID: 11790292 Published · ppublish English Journal Article Review

Small artery remodeling in hypertension.

Current hypertension reports ·Vol. 4 ·No. 1 ·2002-02-00 ·Pages 49-55

Mulvany MJ

Abstract

Hypertension is associated with altered structure of the resistance vessels, a process known as remodeling. This review summarizes current concepts concerning the structure of a subgroup of the resistance vessels, the small arteries, and the modes of remodeling, some of the determinants of remodeling, and some signaling pathways for remodeling. It is shown that the available evidence points to important roles for blood flow and growth factors, in addition to blood pressure, as causes of resistance artery remodeling. Finally, the relationship between vascular structure and blood pressure is discussed, in particular with regard to the effects of antihypertensive therapy. Here again, it appears that blood flow plays an important role in allowing the correction of the abnormal resistance vessel structure seen in hypertension.

MeSH Terms
Antihypertensive Agents/pharmacology Arteries/anatomy & histology,drug effects,physiology Blood Pressure/physiology Humans Hypertension/physiopathology Mitogen-Activated Protein Kinase 3 Mitogen-Activated Protein Kinases/metabolism Receptor, Platelet-Derived Growth Factor beta/metabolism Signal Transduction/physiology Vascular Resistance/drug effects,physiology
Chemicals
Antihypertensive Agents Receptor, Platelet-Derived Growth Factor beta Mitogen-Activated Protein Kinase 3 Mitogen-Activated Protein Kinases
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Mulvany Michael J
Department of Pharmacology, Aarhus University, University Park 240, 8000 Aarhus C, Denmark. mm@farm.au.dk
References (45)
45 references, click to expand
  1. Vascular structure enhances regional resistance responses in mild essential hypertension.
    J Hypertens. 1988 Jan;6(1):41-8 PMID: 3351293
  2. Small artery structure in hypertension. Dual processes of remodeling and growth.
    Hypertension. 1993 Apr;21(4):391-7 PMID: 8458640
  3. Vascular hypertrophy and remodeling in secondary hypertension.
    Hypertension. 1996 Nov;28(5):785-90 PMID: 8901824
  4. Transactivation: a novel signaling pathway from angiotensin II to tyrosine kinase receptors.
    J Mol Cell Cardiol. 2001 Jan;33(1):3-7 PMID: 11133218
  5. Mechanical stress-initiated signal transductions in vascular smooth muscle cells.
    Cell Signal. 2000 Jul;12(7):435-45 PMID: 10989277
  6. Vascular smooth muscle growth: autocrine growth mechanisms.
    Physiol Rev. 2001 Jul;81(3):999-1030 PMID: 11427690
  7. Effects of antihypertensive therapy on hypertensive vascular disease.
    Curr Hypertens Rep. 2000 Jun;2(3):280-8 PMID: 10981161
  8. Endothelial dysfunction in hypertension is independent from the etiology and from vascular structure.
    Hypertension. 1998 Jan;31(1 Pt 2):335-41 PMID: 9453325
  9. Left ventricular hypertrophy and coronary microcirculation in hypertensive heart disease.
    Blood Press Suppl. 1997;2:6-12 PMID: 9495619
  10. Intracellular pH in human resistance arteries in essential hypertension.
    Hypertension. 1991 Jun;17 (6 Pt 1):780-6 PMID: 1646163
  11. Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation.
    Circulation. 1998 Jan 27;97(3):230-3 PMID: 9462521
  12. Role of matrix metalloproteinases and their tissue inhibitors in the regulation of coronary cell migration.
    Arterioscler Thromb Vasc Biol. 1999 May;19(5):1150-5 PMID: 10323763
  13. Blunted effects of endothelin upon small subcutaneous resistance arteries of mild essential hypertensive patients.
    J Hypertens. 1992 May;10(5):437-44 PMID: 1317904
  14. Central role of the MAPK pathway in ang II-mediated DNA synthesis and migration in rat vascular smooth muscle cells.
    Arterioscler Thromb Vasc Biol. 1999 Jan;19(1):73-82 PMID: 9888869
  15. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells.
    Pharmacol Rev. 2000 Dec;52(4):639-72 PMID: 11121512
  16. Reduced medication and normalization of vascular structure, but continued hypertension in renovascular patients after revascularization.
    Cardiovasc Res. 2001 Oct;52(1):136-42 PMID: 11557242
  17. Structural properties of rat mesenteric small arteries after 4-wk exposure to elevated or reduced blood flow.
    Am J Physiol. 1997 Oct;273(4 Pt 2):H1699-706 PMID: 9362233
  18. Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants.
    Hypertension. 2000 Sep;36(3):312-8 PMID: 10988257
  19. Src is an important mediator of extracellular signal-regulated kinase 1/2-dependent growth signaling by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients.
    Hypertension. 2001 Jul;38(1):56-64 PMID: 11463760
  20. Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A.
    Circulation. 1999 Jun 29;99(25):3292-9 PMID: 10385505
  21. Arteriolar and capillary remodelling in hypertension.
    Drugs. 1999;59 Spec No:37-40 PMID: 10548391
  22. Vascular remodeling.
    Hypertension. 1996 Sep;28(3):505-6 PMID: 8794840
  23. The vascular fault in chronic hypertension with particular reference to the role of medial hypertrophy.
    Lancet. 1966 Jun 11;1(7450):1302-4 PMID: 4160883
  24. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan.
    Circulation. 2000 Apr 11;101(14):1653-9 PMID: 10758046
  25. Evidence for increased media thickness, increased neuronal amine uptake, and depressed excitation--contraction coupling in isolated resistance vessels from essential hypertensives.
    Circ Res. 1987 Aug;61(2):181-6 PMID: 3621484
  26. Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension.
    Hypertension. 1994 Jan;23(1):83-91 PMID: 8282334
  27. Vasodilatation, not hypotension, improves resistance vessel design during treatment of essential hypertension: a literature survey.
    J Hypertens. 2001 Jun;19(6):1001-6 PMID: 11403346
  28. The impact of atherosclerotic arterial remodeling on percentage of luminal stenosis varies widely within the arterial system. A postmortem study.
    Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):3057-63 PMID: 9409293
  29. Angiotensin II stimulates extracellular signal-regulated kinase activity in intact pressurized rat mesenteric resistance arteries.
    Hypertension. 2000 Oct;36(4):617-21 PMID: 11040245
  30. Location of resistance arteries.
    J Vasc Res. 2001 Jan-Feb;38(1):1-12 PMID: 11173989
  31. Elevated pressure stimulates protooncogene expression in isolated mesenteric arteries.
    Am J Physiol. 1996 Oct;271(4 Pt 2):H1517-23 PMID: 8897947
  32. Effects of an angiotensin-converting enzyme inhibitor and a beta-blocker on cerebral arteriolar dilatation in hypertensive rats.
    Hypertension. 2001 Jun;37(6):1388-93 PMID: 11408382
  33. Differential effects of pressure and flow on DNA and protein synthesis and on fibronectin expression by arteries in a novel organ culture system.
    Circ Res. 1995 Oct;77(4):684-94 PMID: 7554114
  34. Src tyrosine kinases and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases mediate pressure-induced c-fos expression in cannulated rat mesenteric small arteries.
    Hypertension. 2001 Mar;37(3):955-60 PMID: 11244024
  35. Organoid culture of cannulated rat resistance arteries: effect of serum factors on vasoactivity and remodeling.
    Am J Physiol Heart Circ Physiol. 2000 Apr;278(4):H1233-40 PMID: 10749719
  36. Structural determinants of vascular resistance properties in hypertension. Haemodynamic and model analysis.
    J Vasc Res. 1992 Jul-Aug;29(4):293-312 PMID: 1391553
  37. Structure and function of small arteries.
    Physiol Rev. 1990 Oct;70(4):921-61 PMID: 2217559
  38. Effects of protection from pressure on resistance artery morphology and reactivity in spontaneously hypertensive and Wistar-Kyoto rats.
    Circ Res. 1991 May;68(5):1230-40 PMID: 2018988
  39. Histology of subcutaneous small arteries from patients with essential hypertension.
    Hypertension. 1993 Oct;22(4):523-6 PMID: 8406657
  40. Increased pressure induces sustained protein kinase C-independent herbimycin A-sensitive activation of extracellular signal-related kinase 1/2 in the rabbit aorta in organ culture.
    Circ Res. 1997 Dec;81(6):895-903 PMID: 9400369
  41. Angiotensin II induces vascular smooth muscle cell replication independent of blood pressure.
    Hypertension. 1998 Jun;31(6):1331-7 PMID: 9622150
  42. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension.
    Hypertension. 1995 Apr;25(4 Pt 1):474-81 PMID: 7721386
  43. Prazosin administration enhances proliferation of arteriolar adventitial fibroblasts.
    Microvasc Res. 1998 Mar;55(2):138-45 PMID: 9521888
  44. The blood pressure seeking properties of the central nervous system.
    J Hypertens. 1988 Mar;6(3):177-85 PMID: 3283225
  45. Smooth muscle cell changes during flow-related remodeling of rat mesenteric resistance arteries.
    Circ Res. 2001 Jul 20;89(2):180-6 PMID: 11463726
Article Info
Journal
Current hypertension reports
Abbr.
Curr Hypertens Rep
ISSN
1522-6417
DOI
10.1007/s11906-002-0053-y
Email
mm@farm.au.dk
Published
2002-02-00
Pages
49-55
Language
English
Region
United States
NLM ID
100888982
Subset
IM
External Links
PubMed source DOI: 10.1007/s11906-002-0053-y View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2